SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a recent rebound that traders say held its gains, with bullish technical setups and positioning ahead of earnings. The upbeat view contrasts with concerns that high rates and a sluggish housing market could continue to weigh on renovation demand.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sharp rally to fresh multi-year highs is drawing attention, with traders citing rotation into defensive, dividend-paying pharma stocks and positioning ahead of the quarterly report. Bulls see a technical breakout and pipeline momentum, while skeptics warn the move may meet resistance and point to patent-expiration and growth concerns.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,397.34014094 USD and is up 0.28 over the last 24 hours. It is currently trading on 12773 active market(s) with $12,152,377,915.37 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid concerns over Binances reported major hack and paused withdrawals, with traders debating whether damaged exchange trust could trigger further selling. Others argue the market is absorbing the shock and point to Binances reported reimbursement progress and planned withdrawal reopening as reasons for optimism.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on expected Q3 results and the Phase 3 QUILT-2.005 topline for ANKTIVA plus BCG in BCG-naive bladder cancer; the trial is database-locked, with a supplemental filing planned if results support it. Bullish traders see the readout and ANKTIVAs expanded bladder-cancer label as growth catalysts, while others question commercial uptake and point to competition, short-selling, and broader market weakness to explain the volatility.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders use the leveraged inverse Nasdaq ETF to hedge or bet on further weakness in tech, citing concerns about AI spending and valuations alongside recent tech-led selling. The community is divided: some expect more downside, while others warn that rumors of a U.S.Iran deal and a possible market rebound could reverse gains in the short ETF.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is being discussed amid volatile, uneven trading across major indexes, with traders watching Fed policy and rising Treasury yields as pressures on equities. Some see relative strength in the Dow as money rotates away from tech, while others warn that inflation, oil-market risks and weakening momentum could deepen a selloff.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Discussion centers on BioCrysts upcoming quarterly results and whether continued ORLADEYO growth can support the stock despite its weak performance. Traders are also looking ahead to Navenibart and Netherton data, while debating managements acquisition strategy and expressing frustration over dilution and limited shareholder returns; buyout talk remains speculative.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results and outlook are drawing attention, with traders highlighting stronger streaming profitability and resilient theme-park performance. The reaction is mixed: some see support for a turnaround, while others point to the stocks persistent range-bound price action and difficulty holding gains.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its upcoming earnings report, with traders watching whether guidance holds and how management addresses pressure on the pharmacy benefit management business. Some see the recent pullback as a potential technical rebound setup, while others remain cautious after the stocks recent selling.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp volatility spike has lifted UVIX, drawing traders seeking a hedge against a broader market pullback. The community is split between expecting volatility to persistciting concerns about oil, interest rates and geopolitical risksand warning that UVIX can quickly lose value as volatility fades and its leveraged futures exposure decays.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is H. B. Fuller (FUL) Up 1.8% Since Last Earnings Report?

H. B. Fuller (FUL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why H. B. Fuller (FUL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

H.B. Fuller Board Unanimously Rejects Second Unsolicited, Non-Binding Proposal for Building Adhesive Solutions Segment

H.B. Fuller Company (H.B. Fuller or the Company) (NYSE: FUL), the worlds largest pureplay adhesives company, today announced that following a thorough review supported by independent financial and legal advisors, its Board of Directors has unanimously rejected Ancoras second unsolicited...

H.B. Fuller Prices $850M Debt Offering to Fund AMS Acquisition

FUL prices $850M in senior notes to finance its AMS acquisition and refinance debt, with a 7.625% coupon and a key redemption condition tied to the deal.

H.B. Fuller Announces Pricing of $850 Million Debt Offering

H.B. Fuller Company (H.B. Fuller) (NYSE:FUL) announced today that it has priced an offering of $850 million aggregate principal amount of 7.625% new senior unsecured notes due 2034 (the Notes) at an issue price of 100% of the principal amount, in a private offering (the Notes Offering) that is...

H. B. Fuller (FUL) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Director Of H.B. Fuller Makes $100K Buy

On September 30, DANIEL FLORNESS, Director at H.B. Fuller (NYSE:FUL) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: In a recent Form 4 filing with the U.S. Securities andread more...

Teresa Trangsrud Rasmussen's Recent Buy: Acquires $99K In H.B. Fuller Stock

It was revealed in a recent SEC filing that Teresa Trangsrud Rasmussen, Board Member at H.B. Fuller (NYSE:FUL) made a noteworthy insider purchase on September 30,.
What Happened: In a recent Form 4 filing with the U.S.read more...

Insider Move: THOMAS HANDLEY Invests $98K In H.B. Fuller Stock

A new SEC filing reveals that THOMAS HANDLEY, Board Member at H.B. Fuller (NYSE:FUL), made a notable insider purchase on September 30,.
What Happened: HANDLEY's recent move, as outlined in a Form 4 filing with theread more...

Board Member Of H.B. Fuller Makes $100K Buy

It was revealed in a recent SEC filing that Srilata Zaheer, Board Member at H.B. Fuller (NYSE:FUL) made a noteworthy insider purchase on September 30,.
What Happened: In a recent Form 4 filing with the U.S. Securitiesread more...

H.B. Fuller Co. engages in the manufacture and marketing of adhesives, sealants, and other chemical products. It operates through the following business segments: Hygiene, Health, and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. The Hygiene, Health, and Consumable Adhesives segment supplies adhesive products in the assembly, packaging, converting, nonwoven, hygiene, health and beauty, flexible packaging, graphic arts, and envelope markets. The Engineering Adhesives segment provides adhesives to the transportation, electronics, medical, clean energy, aerospace and defense, performance wood, insulating glass, textile, appliance, and heavy machinery markets. The Construction Adhesives segment manufactures adhesives, sealants, tapes, mortars, and grouts for construction activities. The company was founded by Harvey Benjamin Fuller in 1887 and is headquartered in St. Paul, MN.

H.B. Fuller Company

H.B. Fuller Sees $55M Synergy Potential From AMS Deal – But Investors Are Still Selling FUL Stock 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>H.B. Fuller made a cash offer of £2.85 per share for Advanced Medical Solutions shareholders.</li><li>The company expects about $55 million in combined run-rate revenue and cost synergies by 2031.</li><li>AMS is also expected to increase H.B. Fuller’s annual revenue by roughly $300 million while creating revenue growth and EBITDA opportunities.</li></ul><p>H.B. Fuller (FUL), the world’s largest pure-play adhesives maker, on Thursday said it would acquire UK-based Advanced Medical Solutions Group Plc in a cash deal valued at £715 million&nbsp;(about $941.8 million).</p><p>At the time of writing, FUL stock was down over 6% in Thursday's premarket trading.</p><h2 class="st-heading-2"><strong>Why H.B. Fuller Is Buying AMS</strong></h2><p>H.B. Fuller, the Minnesota-based adhesive maker, said the acquisition of Advanced Medical Solutions (AMS) would broaden its portfolio and add a medical adhesives segment to its overall product offerings.</p><p>“We have long been clear that medical is a core strategic growth market for H.B. Fuller given its durable demand trends, high regulatory-based entry barriers, and margin profile. Accordingly, we have thoroughly analyzed this structurally scarce market to identify the most attractive assets and growth opportunities,” said Celeste Mastin, President and Chief Executive Officer at H.B. Fuller.</p><h2 class="st-heading-2"><strong>Why Does The Deal Matter To FUL?</strong></h2><p>The company said that the deal would grow its capabilities across tissue bonding adhesives, tapes and dressings, and formulated bio-surgicals segments and result in bringing its total addressable market to $95 billion from $80 billion.</p><p>H.B. Fuller will also be able to leverage AMS’s pan-European salesforce and create cross-selling opportunities for its current portfolio, while AMS can utilize H.B. Fuller’s U.S. infrastructure and distribution network of market leaders to accelerate U.S. penetration.</p><p>The firm noted that it expects to capture about $55 million in combined run-rate revenue and cost synergies by 2031. AMS is also expected to increase H.B. Fuller’s annual revenue by roughly $300 million while creating revenue growth and earnings before interest, taxes , depreciation and amortization (EBITDA) opportunities.&nbsp;&nbsp;</p><h2 class="st-heading-2"><strong>FUL - AMS&nbsp;Deal Contours</strong></h2><p>According to the proposed deal, each eligible AMS shareholder will get £2.85 per share in cash, implying a total enterprise value of £715 million. The transaction will be 100% financed through a committed financing, H.B. Fuller said.</p><p>The deal is expected to close by the end of this calendar year.</p><h2 class="st-heading-2"><strong>FUL Q2 Earnings Print</strong></h2><p>On Wednesday, H.B. Fuller reported second-quarter revenue of $950 million, ahead of analysts' expectations of $924 million, while adjusted earnings of $1.41 per share came in more than Wall Street estimates of $1.38, according to Fiscal.ai data.</p><h2 class="st-heading-2"><strong>What Retail Thinks Of FUL</strong></h2><p>On Stocktwits, retail sentiment surrounding the stock has remained ‘bullish’ amid ‘high’ message volumes in the past 24 hours.</p><p><a href="https://stocktwits.com/symbol/FUL">FUL stock</a> has gained over 7% so far this year.</p><p>(£1 = $1.32)</p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p><p>Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/ibm-sub-1nm-chip-technology-100-billion-transistors/cZ1GgODR7Qu">IBM Just Packed 100B Transistors Into A Fingernail-Sized Sub-1nm Chip — Is It Rewriting Moore's Law?</a></p>

In this photo illustration, the H.B. Fuller company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The Acquisition of Advanced Medical Solutions would broaden H.B. Fuller’s product portfolio and add a medical adhesives segment to its overall product offerings.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.36	--	--	N/A
Q3 '26	$1.47	$1.52	3.74%	BEAT
Q2 '26	$1.40	$1.41	0.91%	BEAT
Q1 '26	$0.55	$0.57	2.72%	BEAT
Q4 '25	$1.23	$1.28	4.25%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

FUL Earnings

Upcoming Earnings: Q4 '26

Historical Earnings